Doxazosin Mesylate
Product Images NDC 10544-292

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Doxazosin Mesylate (NDC 10544-292). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Blenheim Pharmacal, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Graphic- 1mg 90s (Label Graphic 1mg 90s)

Doxazosin Mesylate Tablets USP 1 mg label from Blenheim Pharmacal, Inc. The label indicates a package of 90 tablets, Rx only. Storage instructions specify controlled room temperature 20°-25°C (68°-77°F) and to keep in a light-resistant container away from children. The label includes the NDC 10544-629-90 and manufacturing code 67253-380-11. Four identical panels list the product name, quantity, NDC, manufacturing lot, and expiration date placeholders.*

FDA Label Image

Label Graphic- 4mg 90s (Label Graphic 4mg 90s)

Doxazosin Mesylate Tablets USP 4 mg label for a 90-tablet package from Blenheim Pharmacal, Inc. The label includes NDC 10544-292-90 and manufacturing code 67253-382-11. It states storage instructions at controlled room temperature (20-25°C), Rx only, and advises dosage per package insert. The label shows lot and expiration date placeholders and includes a barcode.*

FDA Label Image

Doxazosin Mesylate Molecular Structure (Image 01)

Chemical structure of doxazosin mesylate, showing its molecular framework including fused rings and various functional groups characteristic of this active ingredient.*

FDA Label Image

Table 1. Summary Of Effectiveness Data In Placebo-controlled Trials (Image 02)

Table 1 summarizes effectiveness data from placebo-controlled trials of Doxazosin Mesylate, showing symptom scores and maximum flow rate changes for different doses (4 mg, 8 mg) compared to placebo. The table includes data from three studies with mean baseline and mean change values, plus a bar graph illustrating maximum flow rate and symptom score changes in Study 2.*

FDA Label Image

Graph: Mean Change In Total Symptom Score From Baseline (Image 03)

A line graph titled 'Figure 1-Study 1' showing the mean change in total symptom score from baseline over a 14-week treatment period. It compares two groups, one receiving doxazosin mesylate (N=50) and the other placebo (N=47). The y-axis represents mean change, ranging from 0 to -6, and the x-axis represents duration of treatment in weeks from 0 to 14. The doxazosin mesylate group shows a greater decrease in symptoms over time compared to the placebo group.*

FDA Label Image

Graph: Mean Increase In Maximum Urinary Flow Rate (ml/sec) From Baseline (Image 04)

A line graph showing the mean increase in maximum urinary flow rate (mL/sec) from baseline over treatment duration in weeks. The graph compares doxazosin mesylate treatment with placebo, indicating greater improvements with doxazosin mesylate. Significant differences from placebo and baseline are marked with asterisks. Sample sizes are 50 for doxazosin mesylate and 47 for placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.